GENERIC STEP THERAPY PLANS (GSTP)

DRUG CLASS	**NASAL STEROIDS**
PGST SSB – Ref# 370-D:	**Beconase AQ, Omnaris, Qnasl, Zetonna**
HPGST SSB – Ref# 404-D:	**Beconase AQ, Dymista, Omnaris, Qnasl, Zetonna**
TGST SSB – Ref# 380-D:	**Beconase AQ, Dymista, Omnaris, Qnasl, Zetonna**

Status: CVS Caremark Criteria
Type: Initial Step Therapy; Post Step Therapy Prior Authorization

INITIAL STEP THERAPY
If the patient has filled a prescription for at least a 30 day supply of a generic nasal steroid within the past 180 days under a prescription benefit administered by CVS Caremark, then the requested branded drug will be paid under that prescription benefit. If the patient does not meet the initial step therapy criteria, then the system will reject with a message indicating that a prior authorization (PA) is required. The prior authorization criteria would then be applied to requests submitted for evaluation to the PA unit.

COVERAGE CRITERIA
Branded nasal steroids will be covered with post step therapy prior authorization when the following criteria are met:

- Patient has experienced an inadequate treatment response, intolerance, or contraindication to at least one generic nasal steroid.

RATIONALE
If the patient has filled a prescription for at least a 30 day supply of a generic nasal steroid within the past 180 days under a prescription benefit administered by CVS Caremark, then the requested branded drug will be paid under that prescription benefit.

If the patient does not meet the initial step therapy criteria, then prior authorization is required.

If the patient has a documented contraindication to or a potential drug interaction with a generic drug, then the requested brand drug will be covered. If the patient is intolerant to at least one of the generic drugs, then the requested brand drug will be covered. If the patient has tried one of the generic drugs for at least 30 days and had an inadequate treatment response, then the requested brand drug will be covered. If these requirements are met, then the approval duration is 24 months.

REFERENCES
N/A

Written by:	UM Development
Date Written:	04/2009
Revised:	09/2009, 10/2009, 07/2010, 05/2011, 06/2011, 01/2012 (added Zetonna), 02/2012 (added Qnasl), 09/2012 (updated formatting and documentation & removed Omnaris), 10/2012 (removing documentation), 01/2013 (added Dymista), 02/2013 (added Omnaris), 05/2013 (added Veramyst to PGST), 11/2013 (reworded question #2, streamlined order of questions), 08/2014 (removed Rhinocort Aqua), 11/2014, 11/2015, 04/2016 (removed Nasonex from TGST), 11/2016 (no changes), (SF) 11/2017 (removed Dymista and Veramyst from PGST, Veramyst from HPGST and TGST)
Reviewed:	Medical Affairs 05/2009, 09/2009, 10/2009, 07/2010, 06/2011, 01/2012, (KP) 02/2012; (DC) 09/2012; 01/2013, 02/2013, 05/2013, (LS) 11/2013, (DC) 08/8014, (DC) 11/2014
External Review:	05/2009, 12/2009, 12/2010, 04/2012, 02/2013, 04/2014, 02/2015, 02/2016, 02/2017, 02/2018

CRITERIA FOR APPROVAL

1	Has the patient demonstrated an inadequate treatment response after at least a 30 day trial of a generic nasal steroid? [If yes, then no further questions.]	Yes	No
2	Does the patient have a documented contraindication to or a potential drug interaction with a generic nasal steroid? [If yes, then no further questions.]	Yes	No
3	Has the patient had a trial and was intolerant to at least one generic nasal steroid?	Yes	No

Guidelines for Approval					
Duration of Approval			**24 Months**		
Set 1 – Failed Trial		**Set 2 – Contraindication**		**Set 3 – Intolerance**	
Yes to question(s)	**No to question(s)**	**Yes to question(s)**	**No to question(s)**	**Yes to question(s)**	**No to question(s)**
1	None	2	1	3	1
					2

Mapping Instructions		
	Yes	**No**
1	Approve for 24 months	Go to 2
2	Approve for 24 months	Go to 3
3	Approve for 24 months	Deny